BriaCell Therapeutics Corp.

TSX:BCT.TO

Biotechnology

Healthcare
$5.75 +18.88%

+$0.94 today

Market cap
$50.02M
Beta
1.53
P/E (TTM)
-0.3
EPS (TTM)
-$4.23
52W Low $3.68High $20.40

Volume 0.00M

Average 0.01M

BCT.TO Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

BriaCell Therapeutics Corp.TSX: BCT.TO

Depreciation & Amortization · Q3 FY2026 · quarter ended Apr 2026

Depreciation & amortization growth accelerates

Q3 FY2026 depreciation & amortization of $33.01K rose 23.8% year over year, ahead of the -25.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 23.8% from the prior quarter. Over 3 fiscal years it compounded at +91.9% a year.

Context

  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +23.8% holds above the trailing-twelve-month pace of -25.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterApr 2026
$33.01K+23.8% QoQ
Last fiscal yearJul 2025
$107.93K+28.6% YoY
LTMApr 2026
$112.91K-25.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+23.8%——
1 year+28.6%——
3-year CAGR+91.9%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
107.93K USD
Year-over-year change
+28.6%
4-year CAGR
+62.3%

Depreciation & Amortization vs competitors

How BCT.TO compares with its peers on the latest reported figures

No competitor Depreciation & Amortization figures are available to compare.

Income Statement

USD
Metric
FY2021
Jul 2021
FY2022
Jul 2022
FY2023
Jul 2023
FY2024
Jul 2024
FY2025
Jul 2025
Revenue00000
Cost of Revenue15.55K000107.93K
Gross Profit(15.55K)000(107.93K)
Gross Margin—————
Research & Development2.02M8.02M15.34M27.18M21.53M
Selling, General & Admin4.96M7.27M7.94M6.15M5.9M
Operating Expenses6.97M15.29M23.27M33.33M27.43M
Depreciation & Amortization15.55K15.27K15.27K83.9K107.93K
EBITDA(7.1M)(26.82M)(23.26M)(4.85M)(27.43M)
EBITDA Margin—————
Operating Income(7.11M)(15.29M)(23.27M)(33.33M)(27.54M)
Operating Margin—————
Interest Income3.21K136.73K891.21K288.02K121.42K
Interest Expense80.09K9790037.43K
Other Income / Expenses(6.84M)(11.55M)2.97M28.4M656.6K
Income Before Tax(13.82M)(26.84M)(20.3M)(4.93M)(26.88M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(13.82M)(26.84M)(20.3M)(4.79M)(26.63M)
Net Margin—————
EPS (Basic)(467.51)(259.50)(195.00)(43.68)(62.95)
EPS (Diluted)(467.51)(259.50)(195.00)(43.68)(62.95)
Weighted Avg Shares30.13K103.29K104.13K109.7K423.11K
Weighted Avg Shares (Diluted)30.13K103.29K104.13K109.7K423.11K

BriaCell Therapeutics Corp.

TSX:BCT.TO

Intrinsic Alpha fair value

Locked

Current Price

$5.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.